RNS Number : 4139O Renalytix PLC 10 June 2022 Renalytix plc ("Renalytix" or the "Company") 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX TM Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients Late-breaking data presented at American
RNS Number : 0740O Renalytix PLC 08 June 2022 Renalytix to Present at 42 nd Annual William Blair Growth Stock Conference NEW YORK and SALT LAKE CITY , June 8, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth
RNS Number : 6870N Renalytix PLC 06 June 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix held Two Data Presentations on KidneyIntelX at American Diabetes Association 82 nd Scientific Sessions® Real-world clinical utility in 1,112 patients tested with KidneyIntelX KidneyIntelX
RNS Number : 6872N Renalytix PLC 06 June 2022 Renalytix plc ("Renalytix" or the "Company") KidneyIntelX TM Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort Data shared in oral presentation at American
RNS Number : 9425J Renalytix PLC 29 April 2022 Renalytix plc (" Renalytix " or the " Company ") Total voting rights NEW YORK and SALT LAKE CITY , 29 April, 2022 - Renalytix (LSE: RENX) announces that t he Company's total issued share capital consists of 74,760,432 shares of 0.25 pence
RNS Number : 9726I Renalytix PLC 22 April 2022 Renalytix plc ("Renalytix" or the "Company") Grant of Share Options New York and SALT LAKE CITY , April 22, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Remuneration Committee has agreed to issue options over a total
RNS Number : 7218H Renalytix PLC 08 April 2022 Renalytix plc ("Renalytix" or the "Company") Issue of shares NEW YORK and SALT LAKE CITY , 8 April, 2022 - Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new
RNS Number : 7737H Renalytix PLC 08 April 2022 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR
RNS Number : 7325G Renalytix PLC 31 March 2022 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR
RNS Number : 6807G Renalytix PLC 31 March 2022 Renalytix plc ("Renalytix" or the "Company") Half Year Report LONDON and SALT LAKE CITY , March 31, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE : RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing